Loading
Jun Guo built China's melanoma programme around the acral and mucosal subtypes common in Asia, and led the trials that made toripalimab the first domestic PD-1 antibody approved.
Guo's department at Peking University Cancer Hospital is the largest melanoma unit in Asia; he led the registration study of toripalimab in previously treated melanoma (China's first domestic PD-1 approval, December 2018), trials of toripalimab plus axitinib in mucosal melanoma, and work defining KIT and other targets in acral melanoma. Past president of CSCO.
Shares Chinese Society of Clinical Oncology and the tag china.
Shares Chinese Society of Clinical Oncology and the tag china.
Shares Peking University Cancer Hospital and the tag china.
Shares Peking University Cancer Hospital and the tag china.
Shares Toripalimab and the tag china.
Shares Toripalimab and the tag china.
Shares Renal cell carcinoma and the tag china.
Shares Renal cell carcinoma and the tag china.